Shares of Lupin Ltd were trading in the green and 2% higher on 31 December after the company announced that it had acquired Huminsulin in India from Eli Lilly to increase its diabetic portfolio.
Lupin has been pushing the Huminsulin family of medications, which includes Insulin Human, through its existing Distribution and Promotion Agreements with Eli Lilly, India. The drug huminsulin is advised to improve blood sugar regulation in adults and children with type 1 and type 2 diabetes mellitus.
Insulin therapy is the cornerstone of type 1 diabetes management and is also necessary as type 2 diabetes worsens. Furthermore, according to a press release from Lupin, Insulin Human is advised in combination with other complementary therapies for Type 1 and Type 2 Diabetes Mellitus, which affect a significant percentage of the Indian population.
Lupin focuses on pharmaceutical products, including biotechnology products, complex generics, branded and generic formulations, and active pharmaceutical ingredients. The company holds a significant market share in both India and the United States in several therapeutic areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health.
Lupin has been working hard lately to increase the number of its diabetes medications available in the US. Following the announcement that it will buy three anti-diabetic medications from Boehringer Ingelheim, the company recently announced that it would buy Huminsulin from Eli Lilly. This move is expected to bolster Lupin’s diabetology division, which now makes up around 20% of its domestic portfolio, according to ICICI Securities.
On 13 December 2024, Lupin announced that it will be expanding its diabetes portfolio in the country by purchasing the anti-diabetes trademarks for AJADUO (Empagliflozin + Linagliptin), GIBTULIO (Empagliflozin), and GIBTULIO MET (Empagliflozin + Metformin) from Boehringer Ingelheim International. Together with diet and exercise, these drugs help improve glycemic control in persons with type 2 diabetes mellitus.
At 2:11 pm, the shares of Lupin were trading % higher at Rs 2,363.60 on NSE.
The future of investing is here!
Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!
